Tags

Type your tag names separated by a space and hit enter

[Topical treatment of atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study].
Hautarzt. 2003 Mar; 54(3):248-53.H

Abstract

BACKGROUND

Recent investigations suggest an anti-inflammatory and antibacterial effect of hyperforin, which is a major constituent of Hypericum perforatum L. (Saint John's wort).

OBJECTIVE

In a half-side comparison study we assessed the efficacy of a cream containing Hypericum extract standardized to 1.5% hyperforin (verum) in comparison to the corresponding vehicle (placebo) for the treatment of subacute atopic dermatitis. The study design was a prospective randomized placebo-controlled double-blind single center study.

METHODS

In twenty one patients suffering from mild to moderate atopic dermatitis (mean SCORAD 44.5) the treatment with verum or placebo was randomly allocated to the left or right site of the body, respectively. The patients were treated twice daily over a period of four weeks. Eighteen patients completed the study. The severity of the skin lesions on the left and right site was determined by means of a modified SCORAD-index (primary endpoint).

RESULTS

The intensity of the eczematous lesions improved on both sites of treatment. However, the Hypericum cream was significantly superior to the vehicle at all clinical visits (days 7, 14, 28) (p<0.05). Skin colonization with Staphylococcus aureus was reduced by both verum and placebo, showing a trend to better antibacterial activity of the Hypericum cream (p=0.064). Skin tolerance and cosmetic acceptability was good or excellent with both the Hypericum cream and the vehicle (secondary endpoints).

CONCLUSION

Hypericum cream was significantly superior to its vehicle in the topical treatment of mild to moderate atopic dermatitis. The therapeutic efficacy of the Hypericum cream should be evaluated in further studies with larger patient cohorts, in comparison to standard therapeutic agents (i.e. corticosteroids).

Authors+Show Affiliations

Universitäts-Hautklinik Freiburg. schempp@ haut.ukl.uni-freiburg.deNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase II
Evaluation Study
Journal Article
Randomized Controlled Trial

Language

ger

PubMed ID

12634994

Citation

Schempp, C M., et al. "[Topical Treatment of Atopic Dermatitis With Hypericum Cream. a Randomised, Placebo-controlled, Double-blind Half-side Comparison Study]." Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, vol. 54, no. 3, 2003, pp. 248-53.
Schempp CM, Hezel S, Simon JC. [Topical treatment of atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study]. Hautarzt. 2003;54(3):248-53.
Schempp, C. M., Hezel, S., & Simon, J. C. (2003). [Topical treatment of atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study]. Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, 54(3), 248-53.
Schempp CM, Hezel S, Simon JC. [Topical Treatment of Atopic Dermatitis With Hypericum Cream. a Randomised, Placebo-controlled, Double-blind Half-side Comparison Study]. Hautarzt. 2003;54(3):248-53. PubMed PMID: 12634994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Topical treatment of atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study]. AU - Schempp,C M, AU - Hezel,S, AU - Simon,J C, Y1 - 2003/02/18/ PY - 2003/3/14/pubmed PY - 2003/8/29/medline PY - 2003/3/14/entrez SP - 248 EP - 53 JF - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete JO - Hautarzt VL - 54 IS - 3 N2 - BACKGROUND: Recent investigations suggest an anti-inflammatory and antibacterial effect of hyperforin, which is a major constituent of Hypericum perforatum L. (Saint John's wort). OBJECTIVE: In a half-side comparison study we assessed the efficacy of a cream containing Hypericum extract standardized to 1.5% hyperforin (verum) in comparison to the corresponding vehicle (placebo) for the treatment of subacute atopic dermatitis. The study design was a prospective randomized placebo-controlled double-blind single center study. METHODS: In twenty one patients suffering from mild to moderate atopic dermatitis (mean SCORAD 44.5) the treatment with verum or placebo was randomly allocated to the left or right site of the body, respectively. The patients were treated twice daily over a period of four weeks. Eighteen patients completed the study. The severity of the skin lesions on the left and right site was determined by means of a modified SCORAD-index (primary endpoint). RESULTS: The intensity of the eczematous lesions improved on both sites of treatment. However, the Hypericum cream was significantly superior to the vehicle at all clinical visits (days 7, 14, 28) (p<0.05). Skin colonization with Staphylococcus aureus was reduced by both verum and placebo, showing a trend to better antibacterial activity of the Hypericum cream (p=0.064). Skin tolerance and cosmetic acceptability was good or excellent with both the Hypericum cream and the vehicle (secondary endpoints). CONCLUSION: Hypericum cream was significantly superior to its vehicle in the topical treatment of mild to moderate atopic dermatitis. The therapeutic efficacy of the Hypericum cream should be evaluated in further studies with larger patient cohorts, in comparison to standard therapeutic agents (i.e. corticosteroids). SN - 0017-8470 UR - https://www.unboundmedicine.com/medline/citation/12634994/[Topical_treatment_of_atopic_dermatitis_with_Hypericum_cream__A_randomised_placebo_controlled_double_blind_half_side_comparison_study]_ L2 - https://dx.doi.org/10.1007/s00105-002-0440-y DB - PRIME DP - Unbound Medicine ER -